ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Alharbi, Naif Khalaf; Padron-Regalado, Eriko; Thompson, Craig; Kupke, Alexandra; Wells, Daniel; Sloan, Megan A.; Grehan, Keith; Temperton, Nigel; Lambe, Teresa; Warimwe, George M.; Becker, Stephan; Hill, Adrian V. S.; Gilbert, Sarah C.

doi:10.1016/j.vaccine.2017.05.032

Cited by 145 publications

(147 citation statements)

References 50 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…These recommendations and priority actions in the Doha Declaration will be delivered as a separate document after validation by stakeholders in affected and at risk countries. At least two promising camel vaccine candidates are currently in development and being evaluated in field trials (Haagmans et al, 2016;Alharbi et al, 2017). Stakeholders agreed that the current funding mechanisms need to include risk-mitigating options that target the animal-human interface to prevent zoonotic transmission.…”

Section: Vaccines For Camelsmentioning

confidence: 99%

MERS: Progress on the global response, remaining challenges and the way forward

et al. 2018

View full text Add to dashboard Cite

This article summarizes progress in research on Middle East Respiratory Syndrome (MERS) since a FAO-OIE-WHO Global Technical Meeting held at WHO Headquarters in Geneva on 25-27 September 2017. The meeting reviewed the latest scientific findings and identified and prioritized the global activities necessary to prevent, manage and control the disease. Critical needs for research and technical guidance identified during the meeting have been used to update the WHO R&D MERS-CoV Roadmap for diagnostics, therapeutics and vaccines and a broader public health research agenda. Since the 2017 meeting, progress has been made on several key actions in animal populations, at the animal/human interface and in human populations. This report also summarizes the latest scientific studies on MERS since 2017, including data from more than 50 research studies examining the presence of MERS-CoV infection in dromedary camels.

show abstract

Section: Vaccines For Camelsmentioning

confidence: 99%

MERS: Progress on the global response, remaining challenges and the way forward

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Previous studies have investigated viral vector-based vaccines [8][9][10][11][12], subunit vaccines [13][14][15][16][17], and DNA vaccines [18,19]. Of these, vaccination using viral vectors or DNA immunization successfully generated neutralizing antibodies and protected against infection [12]. However, safety concerns about DNA vaccines and their weak induction of neutralizing antibodies plus the possibility of reduced efficacy of viral vector vaccines because of preexisting immunity against the viral vectors induced by repeated immunization cannot be ignored.…”

Section: Introductionmentioning

confidence: 99%

Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

Jung

Kang

Lee

et al. 2018

Vaccine

View full text Add to dashboard Cite

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.

show abstract

“…Application of the ChAdOx1 platform to a diverse range of emerging pathogens is supported by multiple studies demonstrating that a single dose of ChAdOx1-vectored vaccine fully protected inbred BALB/c mice, sheep, goats, and cattle from lethal Rift Valley fever, protected 100% of transgenic human dipeptidyl peptidase-4 mice from lethal Middle East respiratory syndrome, and offered inbred BALB/c mice sterilising protection from Zika virus infection [107][108][109][110]. Each of these vaccine candidates has potently induced antigen-specific T-cell responses and high titre neutralising antibodies [107][108][109][110][111].…”

Section: Replication-deficient Chimpanzee Adenovirus Vector Platformmentioning

confidence: 97%

Vaccine platforms for the prevention of Lassa fever

2019

Self Cite

View full text Add to dashboard Cite

A B S T R A C TLassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), which is endemic throughout much of West Africa. The virus primarily circulates in the Mastomys natalensis reservoir and is transmitted to humans through contact with infectious rodents or their secretions; human-to-human transmission is documented as well. With the exception of Dengue fever, LASV has the highest human impact of any haemorrhagic fever virus. On-going outbreaks in Nigeria have resulted in unprecedented mortality. Consequently, the World Health Organization (WHO) has listed LASV as a high priority pathogen for the development of treatments and prophylactics. Currently, there are no licensed vaccines to protect against LASV infection. Although numerous candidates have demonstrated efficacy in animal models, to date, only a single candidate has advanced to clinical trials. Lassa fever vaccine development efforts have been hindered by the high cost of biocontainment requirements, the absence of established correlates of protection, and uncertainty regarding the extent to which animal models are predictive of vaccine efficacy in humans. This review briefly discusses the epidemiology and biology of LASV infection and highlights recent progress in vaccine development.

show abstract

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Cited by 145 publications

References 50 publications

MERS: Progress on the global response, remaining challenges and the way forward

MERS: Progress on the global response, remaining challenges and the way forward

Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

Vaccine platforms for the prevention of Lassa fever

Contact Info

Product

Resources

About